A Genetic Progression Model of BrafV600E-Induced Intestinal Tumorigenesis Reveals Targets for Therapeutic Intervention

Cancer Cell

Volumn 24, Issue 1, 2013, Pages 15-29

  Rad, Roland ^a,b,c   Cadiñanos, Juan ^c,d   Rad, Lena ^c   Varela, Ignacio ^e   Strong, Alexander ^c   Kriegl, Lydia ^f   Constantino Casas, Fernando ^g   Eser, Stefan ^a   Hieber, Maren ^a   Seidler, Barbara ^a   Price, Stacey ^c   Fraga, Mario F ^h   Calvanese, Vincenzo ^h,i   Hoffman, Gary ^j   Ponstingl, Hannes ^c   Schneider, Günter ^b   Yusa, Kosuke ^c   Grove, Carolyn ^c   Schmid, RolandM ^a   Wang, Wei ^c   Vassiliou, George ^c   Kirchner, Thomas ^f   McDermott, Ultan ^c   Liu, Pentao ^c   Saur, Dieter ^a,b   Bradley, Allan ^c   more..

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^d Radiation Oncology Department   (Spain)

^e University of Cantabria   (Spain)

^f UNIVERSITY OF MUNICH   (Germany)

^g UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^h UNIVERSITY OF OVIEDO   (Spain)

ⁱ CENTRO NACIONAL DE BIOTECNOLOGÍA   (Spain)

^j UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

APC PROTEIN; ARF PROTEIN; B RAF KINASE; CYCLIN DEPENDENT KINASE INHIBITOR 2A; GEFITINIB; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; N [3 (5 CHLORO 1H PYRROLO[2,3 B]PYRIDINE 3 CARBONYL) 2,4 DIFLUOROPHENYL]PROPANESULFONAMIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PICTILISIB; PROTEIN P53; RETINOBLASTOMA PROTEIN;

ADVANCED CANCER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER MODEL; CANCER STAGING; CARCINOGENESIS; COLORECTAL ADENOMA; COLORECTAL CANCER; COLORECTAL CARCINOMA; CONTROLLED STUDY; DRUG EFFICACY; DRUG SCREENING; DRUG SENSITIVITY; DRUG TARGETING; DYSPLASIA; EARLY CANCER; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FEMALE; GENE ACTIVATION; GENE INACTIVATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HYPERPLASIA; LARGE INTESTINE CANCER; MALE; METASTASIS; MICROSATELLITE INSTABILITY; MISSENSE MUTATION; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SMALL INTESTINE CANCER; SOMATIC MUTATION; TUMOR INVASION; TUMOR SUPPRESSOR GENE;

MUS;

EID: 84880020762     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2013.05.014     Document Type: Article

References (50)

1. Bennecke M., Kriegl L., Bajbouj M., Retzlaff K., Robine S., Jung A., Arkan M.C., Kirchner T., Greten F.R. Ink4a/Arf and oncogene-induced senescence prevent tumor progression during alternative colorectal tumorigenesis. Cancer Cell 2010, 18:135-146.
2. Bettington M., Walker N., Clouston A., Brown I., Leggett B., Whitehall V. The serrated pathway to colorectal carcinoma: current concepts and challenges. Histopathology 2013, 62:367-386.
3. Bond C.E., Umapathy A., Ramsnes I., Greco S.A., Zhao Z.Z., Mallitt K.A., Buttenshaw R.L., Montgomery G.W., Leggett B.A., Whitehall V.L. P53 mutation is common in microsatellite stable, BRAF mutant colorectal cancers. Int. J. Cancer 2011, 130:1567-1576.
4. Burd C.E., Sorrentino J.A., Clark K.S., Darr D.B., Krishnamurthy J., Deal A.M., Bardeesy N., Castrillon D.H., Beach D.H., Sharpless N.E. Monitoring tumorigenesis and senescence invivo with a p16(INK4a)-luciferase model. Cell 2013, 152:340-351.
5. Carragher L.A., Snell K.R., Giblett S.M., Aldridge V.S., Patel B., Cook S.J., Winton D.J., Marais R., Pritchard C.A. V600EBraf induces gastrointestinal crypt senescence and promotes tumour progression through enhanced CpG methylation of p16INK4a. EMBO Mol Med 2010, 2:458-471.
6. Chan T.L., Zhao W., Leung S.Y., Yuen S.T. BRAF and KRAS mutations in colorectal hyperplastic polyps and serrated adenomas. Cancer Res. 2003, 63:4878-4881. Cancer Genome Project.
7. Chappell W.H., Steelman L.S., Long J.M., Kempf R.C., Abrams S.L., Franklin R.A., Bäsecke J., Stivala F., Donia M., Fagone P., et al. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. Oncotarget 2011, 2:135-164.
8. Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., Teague J., Woffendin H., Garnett M.J., Bottomley W., et al. Mutations of the BRAF gene in human cancer. Nature 2002, 417:949-954.
9. Fearon E.R. Molecular genetics of colorectal cancer. Annu. Rev. Pathol. 2011, 6:479-507.
10. Fearon E.R., Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990, 61:759-767.
11. Feldser D.M., Kostova K.K., Winslow M.M., Taylor S.E., Cashman C., Whittaker C.A., Sanchez-Rivera F.J., Resnick R., Bronson R., Hemann M.T., Jacks T. Stage-specific sensitivity to p53 restoration during lung cancer progression. Nature 2010, 468:572-575.
12. Feng Y., Bommer G.T., Zhao J., Green M., Sands E., Zhai Y., Brown K., Burberry A., Cho K.R., Fearon E.R. Mutant KRAS promotes hyperplasia and alters differentiation in the colon epithelium but does not expand the presumptive stem cell pool. Gastroenterology 2011, 141:1003-1013.
13. Flaherty K.T., Infante J.R., Daud A., Gonzalez R., Kefford R.F., Sosman J., Hamid O., Schuchter L., Cebon J., Ibrahim N., et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N.Engl. J. Med. 2012, 367:1694-1703.
14. Flaherty K.T., Robert C., Hersey P., Nathan P., Garbe C., Milhem M., Demidov L.V., Hassel J.C., Rutkowski P., Mohr P., et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N.Engl. J. Med. 2012, 367:107-114. METRIC Study Group.
15. Fujita K., Yamamoto H., Matsumoto T., Hirahashi M., Gushima M., Kishimoto J., Nishiyama K., Taguchi T., Yao T., Oda Y. Sessile serrated adenoma with early neoplastic progression: a clinicopathologic and molecular study. Am. J. Surg. Pathol. 2011, 35:295-304.
16. Garnett M.J., Edelman E.J., Heidorn S.J., Greenman C.D., Dastur A., Lau K.W., Greninger P., Thompson I.R., Luo X., Soares J., et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 2012, 483:570-575.
17. Haigis K.M., Kendall K.R., Wang Y., Cheung A., Haigis M.C., Glickman J.N., Niwa-Kawakita M., Sweet-Cordero A., Sebolt-Leopold J., Shannon K.M., Settleman J., Giovannini M., Jacks T. Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nat. Genet. 2008, 40:600-608.
18. Janssen K.P., el-Marjou F., Pinto D., Sastre X., Rouillard D., Fouquet C., Soussi T., Louvard D., Robine S. Targeted expression of oncogenic K-ras in intestinal epithelium causes spontaneous tumorigenesis in mice. Gastroenterology 2002, 123:492-504.
19. Jass J.R. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology 2007, 50:113-130.
20. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. CA Cancer J. Clin. 2010, 60:277-300.
21. Junttila M.R., Karnezis A.N., Garcia D., Madriles F., Kortlever R.M., Rostker F., Brown Swigart L., Pham D.M., Seo Y., Evan G.I., Martins C.P. Selective activation of p53-mediated tumour suppression in high-grade tumours. Nature 2010, 468:567-571.
22. Kambara T., Simms L.A., Whitehall V.L., Spring K.J., Wynter C.V., Walsh M.D., Barker M.A., Arnold S., McGivern A., Matsubara N., et al. BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum. Gut 2004, 53:1137-1144.
23. Kriegl L., Neumann J., Vieth M., Greten F.R., Reu S., Jung A., Kirchner T. Up and downregulation of p16(Ink4a) expression in BRAF-mutated polyps/adenomas indicates a senescence barrier in the serrated route to colon cancer. Mod. Pathol. 2011, 24:1015-1022.
24. Krimpenfort P., Quon K.C., Mooi W.J., Loonstra A., Berns A. Loss of p16Ink4a confers susceptibility to metastatic melanoma in mice. Nature 2001, 413:83-86.
25. Lin A.W., Barradas M., Stone J.C., van Aelst L., Serrano M., Lowe S.W. Premature senescence involving p53 and p16 is activated in response to constitutive MEK/MAPK mitogenic signaling. Genes Dev. 1998, 12:3008-3019.
26. Madison B.B., Dunbar L., Qiao X.T., Braunstein K., Braunstein E., Gumucio D.L. Cis elements of the villin gene control expression in restricted domains of the vertical (crypt) and horizontal (duodenum, cecum) axes of the intestine. J.Biol. Chem. 2002, 277:33275-33283.
27. Michaloglou C., Vredeveld L.C., Soengas M.S., Denoyelle C., Kuilman T., van der Horst C.M., Majoor D.M., Shay J.W., Mooi W.J., Peeper D.S. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 2005, 436:720-724.
28. Murphy D.J., Junttila M.R., Pouyet L., Karnezis A., Shchors K., Bui D.A., Brown-Swigart L., Johnson L., Evan G.I. Distinct thresholds govern Myc's biological output invivo. Cancer Cell 2008, 14:447-457.
29. Muzni D.M., Bainbridge M.N., Chang K., Dinh H.H. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012, 487:330-337. Cancer Genome Atlas Network.
30. Nikolaev S.I., Rimoldi D., Iseli C., Valsesia A., Robyr D., Gehrig C., Harshman K., Guipponi M., Bukach O., Zoete V., et al. Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma. Nat. Genet. 2012, 44:133-139.
31. Noffsinger A.E. Serrated polyps and colorectal cancer: new pathway to malignancy. Annu. Rev. Pathol. 2009, 4:343-364.
32. Olive K.P., Tuveson D.A., Ruhe Z.C., Yin B., Willis N.A., Bronson R.T., Crowley D., Jacks T. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 2004, 119:847-860.
33. Palmero I., Pantoja C., Serrano M. p19ARF links the tumour suppressor p53 to Ras. Nature 1998, 395:125-126.
34. Prahallad A., Sun C., Huang S., Di Nicolantonio F., Salazar R., Zecchin D., Beijersbergen R.L., Bardelli A., Bernards R. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 2012, 483:100-103.
35. Pratilas C.A., Taylor B.S., Ye Q., Viale A., Sander C., Solit D.B., Rosen N. (V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. Proc. Natl. Acad. Sci. USA 2009, 106:4519-4524.
36. Rad R., Brenner L., Bauer S., Schwendy S., Layland L., da Costa C.P., Reindl W., Dossumbekova A., Friedrich M., Saur D., et al. CD25+/Foxp3+ Tcells regulate gastric inflammation and Helicobacter pylori colonization invivo. Gastroenterology 2006, 131:525-537.
37. Rad R., Rad L., Wang W., Cadinanos J., Vassiliou G., Rice S., Campos L.S., Yusa K., Banerjee R., Li M.A., et al. PiggyBac transposon mutagenesis: a tool for cancer gene discovery in mice. Science 2010, 330:1104-1107.
38. Rajagopalan H., Bardelli A., Lengauer C., Kinzler K.W., Vogelstein B., Velculescu V.E. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 2002, 418:934.
39. Rex D.K., Ahnen D.J., Baron J.A., Batts K.P., Burke C.A., Burt R.W., Goldblum J.R., Guillem J.G., Kahi C.J., Kalady M.F., et al. Serrated lesions of the colorectum: review and recommendations from an expert panel. Am. J. Gastroenterol. 2012, 107:1315-1329. quiz 1314, 1330.
40. Romagosa C., Simonetti S., López-Vicente L., Mazo A., Lleonart M.E., Castellvi J., Ramon y Cajal S. p16(Ink4a) overexpression in cancer: a tumor suppressor gene associated with senescence and high-grade tumors. Oncogene 2011, 30:2087-2097.
41. Rusconi P., Caiola E., Broggini M. RAS/RAF/MEK inhibitors in oncology. Curr. Med. Chem. 2012, 19:1164-1176.
42. Samowitz W.S., Slattery M.L., Sweeney C., Herrick J., Wolff R.K., Albertsen H. APC mutations and other genetic and epigenetic changes in colon cancer. Mol. Cancer Res. 2007, 5:165-170.
43. Sarkisian C.J., Keister B.A., Stairs D.B., Boxer R.B., Moody S.E., Chodosh L.A. Dose-dependent oncogene-induced senescence invivo and its evasion during mammary tumorigenesis. Nat. Cell Biol. 2007, 9:493-505.
44. Sherr C.J., McCormick F. The RB and p53 pathways in cancer. Cancer Cell 2002, 2:103-112.
45. Snover D.C., Ahnen D.J., Burt R.W., Odze R.D. Serrated polyps of the colon and rectum and serrated polyposis. WHO classification of tumors of the digestive system 2010, 160-165. IARC, Lyon. F.T. Bosman, F. Carneiro, R.H. Hruban, N.D. Theise (Eds.).
46. Spring K.J., Zhao Z.Z., Karamatic R., Walsh M.D., Whitehall V.L., Pike T., Simms L.A., Young J., James M., Montgomery G.W., et al. High prevalence of sessile serrated adenomas with BRAF mutations: a prospective study of patients undergoing colonoscopy. Gastroenterology 2006, 131:1400-1407.
47. Torlakovic E., Snover D.C. Serrated adenomatous polyposis in humans. Gastroenterology 1996, 110:748-755.
48. Torlakovic E., Skovlund E., Snover D.C., Torlakovic G., Nesland J.M. Morphologic reappraisal of serrated colorectal polyps. Am. J. Surg. Pathol. 2003, 27:65-81.
49. Yachida S., Mudali S., Martin S.A., Montgomery E.A., Iacobuzio-Donahue C.A. Beta-catenin nuclear labeling is a common feature of sessile serrated adenomas and correlates with early neoplastic progression after BRAF activation. Am. J. Surg. Pathol. 2009, 33:1823-1832.
50. Yang S., Farraye F.A., Mack C., Posnik O., O'Brien M.J. BRAF and KRAS Mutations in hyperplastic polyps and serrated adenomas of the colorectum: relationship to histology and CpG island methylation status. Am. J. Surg. Pathol. 2004, 28:1452-1459.